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Background: The intracerebral hemorrhage (ICH) score is a commonly used prognostic 
model for 30-day mortality in ICH, based on five independent predictors (ICH volume, 
location, Glasgow Coma Scale, age, and intraventricular extension). Use of oral anti-
coagulants (OAC) is also associated with mortality but was not considered in the ICH 
score. We investigated (a) whether the predictive performance of ICH score is similar 
in OAC-ICH and non-OAC-ICH and (b) whether addition of OAC use to the ICH score 
increases the prognostic performance of the score.
Methods: We retrospectively selected all consecutive adult non-traumatic ICH cases 
(three hospitals, region South-Limburg, the Netherlands 2004–2009). Mortality at 
30 days was recorded. Using univariable and multivariable logistic regression, associa-
tion between OAC use and 30-day mortality was tested. Then (a) we computed receiver 
operating characteristic (ROC) curves for ICH score and determined the area under the 
curve (AUC) in OAC-ICH and non-OAC-ICH. Then (b) we created a New ICH score by 
adding OAC use to the ICH score. We calculated correlation between 30-day mortality 
and ICH score, respectively, New ICH score using Spearman correlation test. We com-
puted ROC curves and calculated the AUC.
results: We analyzed 1,232 cases, 282 (22.9%) were OAC related ICH. Overall, 30-day 
mortality was 39.3%. OAC use was independently associated with 30-day mortality 
(OR 2.09, 95% CI, 1.48–2.95; p < 0.001), corrected for the five predictors of the ICH 
score. The ICH score performed slightly better in non-OAC-ICH (AUC 0.840) than in 
OAC-ICH (AUC 0.816), but this difference was not significant (p = 0.39). The ICH score 
and the New ICH score were both significantly correlated with 30-day mortality (rho 0.58, 
p < 0.001 and 0.59, p < 0.001, respectively). The AUC for the ICH score was 0.837, for 
New ICH score 0.840. This difference was not significant.
conclusion: The ICH score is a useful tool for predicting 30-day mortality both in patient 
who use and patients who do not use OAC. Although OAC use is an independent 
predictor of 30-day mortality, addition of OAC use to the existing ICH score does not 
increase the prognostic performance of this score.
Keywords: mortality, intracerebral hemorrhage, oral anticoagulants, intracerebral hemorrhage score, prognosis
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inTrODUcTiOn
Spontaneous non-traumatic intracerebral hemorrhage (ICH) 
constitutes about 10–15% of all strokes and has a high mortality 
of approximately 40% at 1 month (1). To make treatment deci-
sions and being able to determine a prognosis, it is important to 
know which factors predict outcome. Several prediction models 
have been developed (2–8); the most widely used is the ICH 
score (3). Independent predictors for 30-day mortality in the 
ICH score are greater ICH volume, infratentorial location of 
ICH, low score on Glasgow Coma Scale (GCS), older age, and 
intraventricular extension of the hemorrhage.
Up to 25% of all ICH is associated with the use of oral anti-
coagulants (OAC), and this percentage increases with age (9). 
OAC use is associated with larger ICH volume, more hematoma 
expansion, and more intraventricular expansion (3, 10–12). 
Mortality in ICH associated with OAC use (OAC-ICH) is higher 
than in non-OAC-ICH (13, 14). However, most prognostic mod-
els, including ICH score, did not consider or include OAC use. 
Consequently, it is not unequivocally known whether OAC use is 
an additional prognostic factor, independent of the factors in the 
ICH score that are known to have prognostic value. Furthermore, 
whether the predictive performance of ICH score is similar in 
OAC-ICH and non-OAC-ICH has only been investigated in a 
recent small single-center study (15).
Therefore, we aim to determine the prognostic performance of 
ICH score for 30-day mortality in OAC-ICH and non-OAC-ICH 
in a large retrospectively collected multi-center cohort of ICH 
patients. We also aim to test whether OAC use is an independent 
predictor of outcome in ICH patients and if addition of OAC use 
to the ICH score increases the prognostic performance of the 
score.
MaTerials anD MeThODs
Patient selection
We retrospectively collected all consecutive adult (≥18  years) 
patients with an imaging-confirmed (CT- or MRI-scan) non-
traumatic ICH, seen in the emergency department, inpatient 
or outpatient clinic, in three hospitals of South-Limburg, the 
Netherlands, from January 2004 to December 2009. Patients were 
selected using diagnosis-treatment codes retrieved from hospital 
Medical Registration Archives complemented with hospital 
stroke registries. Recurrent ICH cases were included.
Exclusion criteria were traumatic ICH or non-parenchymal 
hemorrhage (e.g., primary subdural, epidural, subarachnoid, or 
intraventricular hemorrhage), hemorrhagic transformation of 
ischemic stroke, brain tumor associated hemorrhage, or hemor-
rhage with a known vascular malformation. Patients with non-
accessible charts and/or scans were also excluded.
The medical ethical committee of Maastricht University 
Medical Center approved the study.
Variables and Definitions
We recorded age, sex, GCS at admission, current OAC use, and 
first INR at admission. OAC-ICH was defined as the occurrence 
of an ICH while on treatment with oral vitamin K antagonists at 
admission. Hemorrhage properties were measured on first CT- or 
MRI-scan: supra- or infratentorial, intraventricular extension, 
and ICH volume. ICH volume was calculated using the ABC/2 
method (16, 17). Survival status and date of death was checked in 
2016 in the hospital registry and the Dutch Municipal Personal 
Records Database. Outcome was defined as mortality at 30 days.
ich score
The ICH score (0–6) was calculated as described by Hemphill 
et al. (3). One point was given for age >80 years, one point for 
infratentorial origin, one point for ICH volume >30  ml, one 
point for intraventricular extension of ICH, one point for a GCS 
of 5–12, and two points for a GCS of 3–4.
We then created a New ICH score by adding an additional 
point for the use of OAC. The maximum New ICH score was 7.
statistical analyses
Categorical variables are presented as frequencies with percent-
age, continuous and ordinal variables as mean with SD or median 
with quartiles, depending on the distribution of the data.
First, we investigated whether OAC use is a predictor of 30-day 
mortality. We performed univariable logistic regression analysis 
with 30-day mortality as outcome variable and the variables in 
the ICH score (age, GCS, intraventricular extension, ICH volume, 
and infratentorial location) and OAC use as predictors. We then 
performed a multivariable logistic regression using the same vari-
ables to see whether OAC use is an independent predictor. There 
were no problems with multicollinearity.
Second, we investigated ICH score in both OAC-ICH and 
non-OAC-ICH. Correlation between ICH score and 30-day 
mortality was determined in patients with OAC-ICH and in 
patients with non-OAC-ICH, using Spearman correlation test. 
We computed receiver operating characteristic (ROC) curves 
and determined the area under the curve (AUC) in OAC-ICH 
and non-OAC-ICH.
Finally, we tested the New ICH score: Spearman correlation 
was determined between ICH score and mortality, and between 
New ICH score and mortality. We computed ROC curves and 
determined and compared the AUC for both ICH score and 
New ICH score. We also computed the difference in net benefit 
between ICH score and New ICH score at a threshold of 90% 
for predicted probability of mortality, which indicates how many 
more true positive mortality classifications can be made with the 
same number of false positive classifications.
Statistical analysis was conducted using IBM SPSSS statistics 
22.0. Analysis of net benefit was performed in R version 3.1.1. 
A p value of <0.05 was considered significant.
resUlTs
We recorded 1,276 consecutive patients with a spontaneous non-
traumatic ICH. Of those, 44 (3%) were excluded due to incom-
plete data on ICH score or 30-day mortality status, which left 
1,232 patients in the analyses. Table 1 presents the characteristics 
of the included patients. Mean age was 73.0 (SD 12.5) years, and 
641 (52.0%) were male. 30-Day mortality was 39.3% (n = 484). 
TaBle 2 | Univariable and multivariable logistic regression analysis for variables predicting 30-day mortality.
30-Day mortality
Univariable analysis Multivariable analysis
Or 95% ci pValue Or 95% ci pValue
Age >80 1.89 1.48–2.41 <0.001 2.01 1.47–2.74 <0.001
Glasgow Coma Scale (GCS) 13–15 1.00 1.00
GCS 5–12 6.59 5.01–8.65 <0.001 3.90 2.86–5.32 <0.001
GCS 3–4 63.85 29.01–140.54 <0.001 27.10 11.85–62.00 <0.001
Infratentorial 1.39 1.02–1.91 0.040 1.95 1.29–2.93 0.001
Intracerebral hemorrhage ICH volume >30 6.90 5.32–8.94 <0.001 4.03 2.93–5.55 <0.001
Intraventricular extension 5.13 4.01–6.57 <0.001 2.52 1.87–3.40 <0.001
OAC use 2.30 1.76–3.02 <0.001 2.09 1.48–2.95 <0.001
TaBle 1 | Patient characteristics.
all intracerebral hemorrhage (ich) patients Oac-ich non-Oac-ich pValue
n = 1,232 n = 282 n = 950
Sex, male (%) 641 (52.0) 155 (55.0) 486 (51.2) 0.261
Age, years (SD) 73.0 (12.5) 77.1 (8.3) 71.7 (13.3) <0.001
Age, >80 (%) 394 (32.0) 117 (41.5) 277 (29.2) <0.001
INR (IQR)a 1.0 (1.0–2.2) 3.5 (2.7–4.4) 1.0 (1.0–1.1) <0.001
Intraventricular extension (%) 526 (42.7) 143 (50.7) 383 (40.3) 0.002
Infratentorial (%) 182 (14.8) 61 (21.6) 121 (12.7) <0.001
ICH volume, cm3 (IQR) 16.0 (4.6–44.1) 20.1 (5.9–60.0) 14.3 (4.3–40.5) 0.001
Volume, >30 cm3 (%) 435 (35.2) 118 (41.8) 317 (33.4) 0.009
Glasgow Coma Scale (GCS) (IQR) 13 (10–15) 13 (8–15) 13 (10–15) 0.004
GCS 13–15 (%) 705 (57.2) 145 (51.4) 560 (58.9) 0.025
GCS 5–12 (%) 418 (33.9) 99 (35.1) 319 (33.6) 0.634
GCS 3–4 (%) 109 (8.8) 38 (13.5) 71 (7.5) 0.002
30-Day mortality (%) 484 (39.3) 155 (55.0) 329 (34.6) <0.001
aINR was available in n = 951 patients (OAC-ICH n = 270 and non-OAC-IC n = 681).
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There were 282 (22.9%) OAC-ICH. Median INR in these patients 
was 3.5 (IQR 2.7–4.4).
Oac Use and 30-Day Mortality
Table 2 shows the associations between 30-day mortality and the 
different variables in the ICH score. All variables, including OAC 
use, showed a significant association with 30-day mortality. In 
multivariable analysis, OAC use was independently associated 
with 30-day mortality (OR 2.09, 95% CI, 1.48–2.95; p < 0.001).
ich score in Oac-ich and non-Oac-ich
The median ICH score in non-OAC-ICH and OAC-ICH are 1 
(IQR 1–3) and 2 (IQR 1–3), respectively (p <  0.001). 30-Day 
mortality in non-OAC-ICH was 329 (34.6%) and in OAC-ICH 
155 (55.0%; p < 0.001).
There was a positive correlation between ICH score and 
mortality in non-OAC-ICH, Spearman’s rho 0.57, p  ≤  0.001. 
Correlation between ICH score and mortality in OAC-ICH was 
also significant, Spearman’s rho 0.56, p ≤ 0.001. The ICH score 
performed slightly better in non-OAC-ICH (AUC of the ROC 
curve 0.840; 95% CI, 0.812–0.867) than in OAC-ICH (AUC 
0.816; 95% CI, 0.767–0.864), but this difference was not signifi-
cant (p = 0.39).
ich score and new ich score including 
Oac Use
An ICH score of 0 was present in 265 (21.5%) patients, and 2 
(0.2%) patients had the maximum ICH score of 6. Both patients 
with an ICH score of 6 used OAC and both died. Mortality in 
patients with different ICH scores is shown in Figure 1A.
Using the new ICH score, 229 (18.6%) patients had a score of 
0, and 2 (0.2%) had the maximum score of 7. All patients with a 
New ICH score of 6 or 7 died. Figure 1B shows the mortality per 
category in the new ICH score.
The ICH score and the New ICH score were both significantly 
correlated with 30-day mortality (Spearman correlation coef-
ficient rho 0.58, p < 0.001 and 0.59, p < 0.001, respectively).
Receiver operating characteristic curves are shown in 
Figure  2. The AUC for the ICH Score was 0.837 (95% CI, 
0.813–0.860), the New ICH score had an AUC of 0.840 (95% 
CI, 0.817–0.863). The difference was not significant (p = 0.36). 
The New ICH score had a net benefit of 0.016 compared with 
the ICH score at a threshold probability of 90% (Figure 3). This 
means that the New ICH score can truly predict 90% mortality 
risk in 1.6% patients more than the ICH score, without any more 
untrue mortality predictions.
FigUre 3 | Net benefit curves for prediction of 30-day mortality by 
intracerebral hemorrhage (ICH) score and New ICH score.
FigUre 2 | Receiver operating characteristic (ROC) curves for intracerebral 
hemorrhage (ICH) score (solid line) and New ICH score (dashed line).
FigUre 1 | 30-Day mortality on different scores of the intracerebral hemorrhage (ICH) score (a) and new ICH score (B).
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DiscUssiOn
In this study, we aimed to investigate the performance of the 
ICH score in predicting 30-day mortality in OAC-ICH and non-
OAC-ICH. ICH score performed equally well in both groups. 
Furthermore, OAC use was an independent predictor of mortal-
ity, but adding OAC use to ICH score did not improve prognostic 
performance.
Predicting an outcome prognosis in ICH patients is important 
as it guides clinical decision making. This accounts especially for 
OAC-ICH, because, despite reversal of OAC which is one of the 
few therapeutic options in ICH, mortality and disability are high. 
Our current understanding of the pathophysiology and the factors 
defining the outcome of OAC-ICH is still limited. Baseline ICH 
volume and GCS at presentation, factors which are incorporated 
in the ICH score, have been identified as independent predictors 
of mortality in both non-OAC and OAC-ICH (18). However, 
other factors that are more prevalent in OAC-ICH than in non-
OAC-ICH such as comorbidities or hematoma and IVH expan-
sion, may also be important determinants of prognosis (10, 13). 
Because these are not included in the ICH score, it might be that 
ICH score would perform less well in OAC-ICH compared with 
spontaneous non-OAC-ICH. We confirmed the performance of 
the ICH score to be comparable in OAC-ICH and non-OAC-ICH. 
Our results are consistent with results that were recently reported 
in a single-center, small (n = 170) study that evaluated hospital 
mortality (15). The results underline the usefulness of the ICH 
score. However, it should be noted that it was recently shown that 
early subjective clinical judgment of physicians correlated even 
more closely with 3-month outcome than ICH score (19) and that 
reassessment after 5 days of care can also improve the accuracy of 
prognosticating outcome in patients with ICH (20).
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Multiple prognostic models (or scores) have been developed 
(2–8) to predict mortality and functional outcome after ICH. 
Although a substantial proportion of all ICH is related to OAC 
use, and OAC use is associated with increased mortality, it is 
striking that many prognostic models such as ICH score and the 
Essen score do not consider OAC use (2, 3). Cheung and Zou 
developed a modified ICH score and considered clotting time 
but it was not an independent predictor and it was therefore not 
included into the modified score (8). In the FUNC score, which 
was developed to predict likelihood of functional independence, 
use of warfarin was described in the baseline characteristics, but 
as it was not an independent predictor, it was not included in the 
final prognostic model (6). The EDICH grading scale included 
INR and showed predictive value for 30-day mortality in a small 
sample of 191 ICHs but has never been used nor validated in 
other studies (5).
In our study, we found OAC use to be a risk factor for 30-day 
mortality, independent of the five components that make up the 
ICH score (ICH volume, age, IVH extension, infratentorial loca-
tion, and GCS). Despite this, adding OAC use to the ICH score 
did not improve the predictive value for mortality as shown in 
the ROC curves. However, comparison of ROC curves warrants 
some methodological reservations (21). It has been shown that 
an independent association of a new risk factor with an outcome 
often does not parallel into improved prediction in ROC curve 
beyond that of basic risk factors, especially when the AUC of the 
basic model already is high. This does not strike out the impor-
tance of the new independent risk factor. The net benefit of the 
New ICH score was, however, not very large compared to the ICH 
score in predicting a high risk of mortality.
Our study has limitations. First, we retrospectively analyzed 
data. Second, withdrawal of treatment could be an important 
confounder in the association with mortality; this affects almost 
all observational studies on outcome in ICH. However, we think 
it is unlikely that OAC use itself might have affected the decision 
of withdrawal of support. Third, we did not record functional 
outcome nor 1-year mortality. Although these are important 
outcome measures, ICH score was developed to predict 30-day 
mortality. Fourth, this study was performed before the era of 
direct OAC (DOAC) and only looked at vitamin K antagonists. 
The results can therefore not be generalized to patients with an 
ICH in the setting of DOAC use. Finally, it could be that antico-
agulation level (INR) or reversal therapy is more important than 
OAC use per se (22). INR values were not available in all patients. 
In OAC-ICH patients in whom INR was measured, 91% had INR 
≥2.0.
In conclusion, the ICH score remains a useful tool for predict-
ing 30-day mortality in patient who use and patients who do 
not use OAC. The use of OAC is associated with higher 30-day 
mortality but adding OAC use to the existing ICH score did not 
improve the predictive value of this score.
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